The role of kallikreins in inflammatory skin disorders and their potential as therapeutic targets

References

• Holick MF, MacLaughlin JA, Clark MB, et al. Photosynthesis of previtamin D3 in human skin and the physiologic consequences. Science. 1980;210(4466):203–205.
   PubMed Web of Science ®Google Scholar
• Slominski A, Wortsman J. Neuroendocrinology of the skin. Endocr Rev. 2000;21(5):457–487.
   PubMed Web of Science ®Google Scholar
• Hennings H, Steinert P, Buxman MM. Calcium induction of transglutaminase and the formation of epsilon(gamma-glutamyl) lysine cross-links in cultured mouse epidermal cells. Biochem Bioph Res Co. 1981;102(2):739–745.
   PubMed Web of Science ®Google Scholar
• Wickett RR, Visscher MO. Structure and function of the epidermal barrier. Am J Infect Control. 2006;34(10):98–110.
   Web of Science ®Google Scholar
• Nemes Z, Steinert PM. Bricks and mortar of the epidermal barrier. Exp Mol Med. 1999;31(1):5–19.
   PubMed Web of Science ®Google Scholar
• Segre JA. Epidermal barrier formation and recovery in skin disorders. J Clin Invest. 2006;116(5):1150–1158.
   PubMed Web of Science ®Google Scholar
• Ohman H, Vahlquist A. In vivo studies concerning a pH gradient in human stratum corneum and upper epidermis. Acta Derm Venereol. 1994;74(5):375–379.
   PubMed Web of Science ®Google Scholar
• Yousef GM, Chang A, Scorilas A, et al. Genomic organization of the human kallikrein gene family on chromosome 19q13.3–q13.4. Biochem Biophys Res Commun. 2000;276(1):125–133.
   PubMed Web of Science ®Google Scholar
• Kraut H, Frey EK, Werle E. Über die inaktivierung des kallikreins (VI. mitteilung Über dieses kreislaufhormon). Hoppe-Seyler’s Z Physiol Chem. 1930;192(1–3):1–21.
   Google Scholar
• Gan L, Lee I, Smith R, et al. Sequencing and expression analysis of the serine protease gene cluster located in chromosome 19q13 region. Gene. 2000;257(1):119–130.
   PubMed Web of Science ®Google Scholar
• Harvey TJ, Hooper JD, Myers SA, et al. Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4. J Biol Chem. 2000;275(48):37397–37406.
   PubMed Web of Science ®Google Scholar
• Yousef GM, Diamandis EP. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev. 2001;22(2):184–204.
   PubMed Web of Science ®Google Scholar
• Komatsu N, Tsai B, Sidiropoulos M, et al. Quantification of eight tissue kallikreins in the stratum corneum and sweat. J Invest Dermatol. 2006;126(4):925–929.
   PubMed Web of Science ®Google Scholar
• Komatsu N, Saijoh K, Toyama T, et al. Multiple tissue kallikrein mRNA and protein expression in normal skin and skin diseases. Br J Dermatol. 2005;153(2):274–281.
   PubMed Web of Science ®Google Scholar
• Yu Y, Prassas I, Muytjens CM, et al. Proteomic and peptidomic analysis of human sweat with emphasis on proteolysis. J Proteomics. 2017;155:40–48.
   PubMed Web of Science ®Google Scholar
• Ishida-Yamamoto A, Simon M, Kishibe M, et al. Epidermal lamellar granules transport different cargoes as distinct aggregates. J Invest Dermatol. 2004;122(5):1137–1144.
   PubMed Web of Science ®Google Scholar
• Ishida-Yamamoto A, Deraison C, Bonnart C, et al. LEKTI is localized in lamellar granules, separated from KLK5 and KLK7, and is secreted in the extracellular spaces of the superficial stratum granulosum. J Invest Dermatol. 2005;124(2):360–366.
   PubMed Web of Science ®Google Scholar
• Shaw JLV, Diamandis EP. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem. 2007;53(8):1423–1432.
   PubMed Web of Science ®Google Scholar
• Lundstrom A, Venereol E. Stratum corneum chymotryptic enzyme: a proteinase which may be generally present in the stratum corneum and with a possible involvement in desquamation. Acta Derm Venereol. 1991;71:471–474.
   PubMed Web of Science ®Google Scholar
• Hansson L, Strömqvist M, Bäckman A, et al. Cloning, expression, and characterization of stratum corneum chymotryptic enzyme. A skin-specific human serine proteinase. J Biol Chem. 1994;269(30):19420–19426.
   PubMed Web of Science ®Google Scholar
• Brattsand M, Egelrud T. Purification, molecular cloning, and expression of a human stratum corneum trypsin-like serine protease with possible function in desquamation. J Biol Chem. 1999;274(42):30033–30040.
   PubMed Web of Science ®Google Scholar
• Ekholm IE, Brattsand M, Egelrud T. Stratum corneum tryptic enzyme in normal epidermis: a missing link in the desquamation process? J Invest Dermatol. 2000;114(1):56–63.
   PubMed Web of Science ®Google Scholar
• Stefansson K, Brattsand M, Ny A, et al. Kallikrein-related peptidase 14 may be a major contributor to trypsin-like proteolytic activity in human stratum corneum. Biol Chem. 2006;387:761–768.
   PubMed Web of Science ®Google Scholar
• Eissa A, Amodeo V, Smith CR, et al. Kallikrein-related peptidase-8 (KLK8) is an active serine protease in human epidermis and sweat and is involved in a skin barrier proteolytic cascade. J Biol Chem. 2011;286(1):687–706.
   PubMed Web of Science ®Google Scholar
• Kishibe M, Baida G, Bhalla P, et al. Important role of kallikrein 6 for the development of keratinocyte proliferative resistance to topical glucocorticoids. Oncotarget. 2016;7(43):69479–69488.
   PubMedGoogle Scholar
• Khoury N, Zingkou E, Pampalakis G, et al. KLK6 protease accelerates skin tumor formation and progression. Carcinogenesis. 2018;39(12):1529–1536.
   PubMed Web of Science ®Google Scholar
• Klucky B, Mueller R, Vogt I, et al. Kallikrein 6 induces E-cadherin shedding and promotes cell proliferation, migration, and invasion. Cancer Res. 2007;67(17):8198–8206.
   PubMed Web of Science ®Google Scholar
• Krenzer S, Peterziel H, Mauch C, et al. Expression and function of the kallikrein-related peptidase 6 in the human melanoma microenvironment. J Invest Dermatol. 2011;131(11):2281–2288.
   PubMed Web of Science ®Google Scholar
• Brattsand M, Stefansson K, Lundh C, et al. A proteolytic cascade of kallikreins in the stratum corneum. J Invest Dermatol. 2005;124(1):198–203.
   PubMed Web of Science ®Google Scholar
• Yoon H, Laxmikanthan G, Lee J, et al. Activation profiles and regulatory cascades of the human kallikrein-related peptidases. J Biol Chem. 2007;282(44):31852–31864.
   PubMed Web of Science ®Google Scholar
• Mägert HJ, Ständker L, Kreutzmann P, et al. LEKTI, a novel 15-domain type of human serine proteinase inhibitor. J Biol Chem. 1999;274(31):21499–21502.
   PubMed Web of Science ®Google Scholar
• Mägert HJ, Kreutzmann P, Ständker L, et al. LEKTI: a multidomain serine proteinase inhibitor with pathophysiological relevance. Int J Biochem Cell B. 2002;34(6):573–576.
   PubMed Web of Science ®Google Scholar
• Deraison C, Bonnart C, Lopez F, et al. LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction. Mol Biol Cell. 2007;18(9):3607–3619.
   PubMed Web of Science ®Google Scholar
• Egelrud T, Brattsand M, Kreutzmann P, et al. hK5 and hK7, two serine proteinases abundant in human skin, are inhibited by LEKTI domain 6. Br J Dermatol. 2005;153(6):1200–1203.
   PubMed Web of Science ®Google Scholar
• Bitoun E, Micheloni A, Lamant L, et al. LEKTI proteolytic processing in human primary keratinocytes, tissue distribution and defective expression in Netherton syndrome. Hum Mol Genet. 2003;12(19):2417–2430.
   PubMed Web of Science ®Google Scholar
• Fortugno P, Bresciani A, Paolini C, et al. Proteolytic activation cascade of the Nethertonsyndrome-defective protein, LEKTI, in the epidermis: implications for skin homeostasis. J Invest Dermatol. 2011;131(11):2223–2232.
   PubMed Web of Science ®Google Scholar
• Schechter NM, Choi EJ, Wang ZM, et al. Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI). Biol Chem. 2005;386(11):1173–1184.
   PubMed Web of Science ®Google Scholar
• Franzke CW, Baici A, Bartels J, et al. Antileukoprotease inhibits stratum corneum chymotryptic enzyme. Evidence for a regulative function in desquamation. J Biol Chem. 1996;271(36):21886–21890.
   PubMed Web of Science ®Google Scholar
• Kobashi M, Morizane S, Sugimoto S, et al. Expression of serine protease inhibitors in epidermal keratinocytes is increased by calcium but not 1,25-dihydroxyvitamin D3 or retinoic acid. Br J Dermatol. 2017;176(6):1525–1532.
   PubMed Web of Science ®Google Scholar
• Morizane S, Yamasaki K, Kabigting FD, et al. Kallikrein expression and cathelicidin processing are independently controlled in keratinocytes by calcium, vitamin D(3), and retinoic acid. J Invest Dermatol. 2010;130(5):1297–1306.
   PubMed Web of Science ®Google Scholar
• Lu J, Goldstein KM, Chen P, et al. Transcriptional profiling of keratinocytes reveals a vitamin D-regulated epidermal differentiation network. J Invest Dermatol. 2005;124(4):778–785.
   PubMed Web of Science ®Google Scholar
• Borgoño CA, Michael IP, Komatsu N, et al. A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. J Biol Chem. 2007;282(6):3640–3652.
   PubMed Web of Science ®Google Scholar
• Caubet C, Jonca N, Brattsand M, et al. Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J Invest Dermatol. 2004;122(5):1235–1244.
   PubMed Web of Science ®Google Scholar
• Harding CR, Aho S, Bosko CA. Filaggrin – revisited. Int J Cosmet Sci. 2013;35(5):412–423.
   PubMed Web of Science ®Google Scholar
• Scott IR, Harding CR, Barrett JG. Histidine-rich protein of the keratohyalin granules. Source of the free amino acids, urocanic acid and pyrrolidone carboxylic acid in the stratum corneum. Biochim Biophys Acta. 1982;719(1):110–117.
   PubMed Web of Science ®Google Scholar
• Gan SQ, McBride OW, Idler WW, et al. Organization, structure, and polymorphisms of the human profilaggrin gene. Biochemistry. 1990;29(40):9432–9440.
   PubMed Web of Science ®Google Scholar
• List K, Szabo R, Wertz PW, et al. Loss of proteolytically processed filaggrin caused by epidermal deletion of matriptase/MT-SP1. J Cell Biol. 2003;163(4):901–910.
   PubMed Web of Science ®Google Scholar
• Resing KA, Al-Alawi N, Blomquist C, et al. Independent regulation of two cytoplasmic processing stages of the intermediate filament-associated protein filaggrin and role of Ca2+ in the second stage. J Biol Chem. 1993;268(33):25139–25145.
   PubMed Web of Science ®Google Scholar
• Pearton DJ, Nirunsuksiri W, Rehemtulla A, et al. Proprotein convertase expression and localization in epidermis: evidence for multiple roles and substrates. Exp Dermatol. 2001;10(3):193–203.
   PubMed Web of Science ®Google Scholar
• Bonnart C, Deraison C, Lacroix M, et al. Elastase 2 is expressed in human and mouse epidermis and impairs skin barrier function in Netherton syndrome through filaggrin and lipid misprocessing. J Clin Invest. 2010;120(3):871–882.
   PubMed Web of Science ®Google Scholar
• Hoste E, Kemperman P, Devos M, et al. Caspase-14 is required for filaggrin degradation to natural moisturizing factors in the skin. J Invest Dermatol. 2011;131(11):2233–2241.
   PubMed Web of Science ®Google Scholar
• Sakabe J, Yamamoto M, Hirakawa S, et al. Kallikrein-related peptidase 5 functions in proteolytic processing of profilaggrin in cultured human keratinocytes. J Biol Chem. 2013;288(24):17179–17189.
   PubMed Web of Science ®Google Scholar
• Nizet V, Ohtake T, Lauth X, et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature. 2001;414(6862):454–457.
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Schauber J, Coda A, et al. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J. 2006;20(12):2068–2080.
   PubMed Web of Science ®Google Scholar
• Sørensen OE, Follin P, Johnsen AH, et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood. 2001;97(12):3951–3959.
   PubMed Web of Science ®Google Scholar
• López-García B, Lee PH, Yamasaki K, et al. Anti-fungal activity of cathelicidins and their potential role in Candida albicans skin infection. J Invest Dermatol. 2005;125(1):108–115.
   PubMed Web of Science ®Google Scholar
• Tokumaru S, Sayama K, Shirakata Y, et al. Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37. J Immunol. 2005;175(7):4662–4668.
   PubMed Web of Science ®Google Scholar
• Derian CK, Eckardt AJ, Andrade-Gordon P. Differential regulation of human keratinocyte growth and differentiation by a novel family of protease-activated receptors. Cell Growth Differ. 1997;8(7):743–749.
   PubMedGoogle Scholar
• Rattenholl A, Steinhoff M. Role of proteinase‐activated receptors in cutaneous biology and disease. Drug Dev Res. 2003;59(4):408–416.
   Web of Science ®Google Scholar
• Steinhoff M, Neisius U, Ikoma A, et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci. 2003;23(15):6176–6180.
   PubMed Web of Science ®Google Scholar
• Rothmeier AS, Ruf W. Protease-activated receptor 2 signaling in inflammation. Semin Immunopathol. 2012;34(1):133–149.
   PubMed Web of Science ®Google Scholar
• Briot A, Deraison C, Lacroix M, et al. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J Exp Med. 2009;206(5):1135–1147.
   PubMed Web of Science ®Google Scholar
• Yamaguchi R, Yamamoto T, Sakamoto A, et al. Mechanism of interleukin-13 production by granulocyte-macrophage colony-stimulating factor-dependent macrophages via protease-activated receptor-2. Blood Cells Mol Dis. 2015;55(1):21–26.
   PubMed Web of Science ®Google Scholar
• Hou L, Kapas S, Cruchley AT, et al. Immunolocalization of protease-activated receptor-2 in skin: receptor activation stimulates interleukin-8 secretion by keratinocytes in vitro. Immunology. 1998;94(3):356–362.
   PubMed Web of Science ®Google Scholar
• Oikonomopoulou K, Hansen KK, Saifeddine M, et al. Proteinase-activated receptors, targets for kallikrein signaling. J Biol Chem. 2006;281(43):32095–32112.
   PubMed Web of Science ®Google Scholar
• Oikonomopoulou K, Hansen KK, Saifeddine M, et al. Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs). Biol Chem. 2006;387(6):817–824.
   PubMed Web of Science ®Google Scholar
• Stefansson K, Brattsand M, Roosterman D, et al. Activation of proteinase-activated receptor-2 by human kallikrein-related peptidases. J Invest Dermatol. 2008;128(1):18–25.
   PubMed Web of Science ®Google Scholar
• Ramachandran R, Eissa A, Mihara K, et al. Proteinase-activated receptors (PARs): differential signalling by kallikrein-related peptidases KLK8 and KLK14. Biol Chem. 2012;393(5):421–427.
   PubMed Web of Science ®Google Scholar
• Egberts F, Heinrich M, Jensen J-M, et al. Cathepsin D is involved in the regulation of transglutaminase 1 and epidermal differentiation. J Cell Sci. 2004;117(Pt 11):2295–2307.
   PubMed Web of Science ®Google Scholar
• Ahmad M, Srinivasula SM, Hegde R, et al. Identification and characterization of murine caspase-14, a new member of the caspase family. Cancer Res. 1998;58(22):5201–5205.
   PubMed Web of Science ®Google Scholar
• Van de Craen M, Van Loo G, Pype S, et al. Identification of a new caspase homologue: caspase-14. Cell Death Differ. 1998;5(10):838–846.
   PubMed Web of Science ®Google Scholar
• Lippens S, Kockx M, Knaapen M, et al. Epidermal differentiation does not involve the pro-apoptotic executioner caspases, but is associated with caspase-14 induction and processing. Cell Death Differ. 2000;7(12):1218–1224.
   PubMed Web of Science ®Google Scholar
• Hvid M, Johansen C, Deleuran B, et al. Regulation of caspase 14 expression in keratinocytes by inflammatory cytokines – a possible link between reduced skin barrier function and inflammation? Exp Dermatol. 2011;20(8):633–636.
   PubMed Web of Science ®Google Scholar
• Netzel-Arnett S, Currie BM, Szabo R, et al. Evidence for a matriptase-prostasin proteolytic cascade regulating terminal epidermal differentiation. J Biol Chem. 2006;281(44):32941–32945.
   PubMed Web of Science ®Google Scholar
• Alef T, Torres S, Hausser I, et al. Ichthyosis, follicular atrophoderma, and hypotrichosis caused by mutations in ST14 is associated with impaired profilaggrin processing. J Invest Dermatol. 2009;129(4):862–869.
   PubMed Web of Science ®Google Scholar
• Basel-Vanagaite L, Attia R, Ishida-Yamamoto A, et al. Autosomal recessive ichthyosis with hypotrichosis caused by a mutation in ST14, encoding type II transmembrane serine protease matriptase. Am J Hum Genet. 2007;80(3):467–477.
   PubMed Web of Science ®Google Scholar
• Barker J, Griffiths CEM, Nickoloff BJ, et al. Keratinocytes as initiators of inflammation. Lancet. 1991;337(8735):211–214.
   PubMed Web of Science ®Google Scholar
• Gröne A. Keratinocytes and cytokines. Vet Immunol Immunopathol. 2002;88(1–2):1–12.
   PubMed Web of Science ®Google Scholar
• Dustin ML, Singer KH, Tuck DT, et al. Adhesion of T lymphoblasts to epidermal keratinocytes is regulated by interferon gamma and is mediated by intercellular adhesion molecule 1 (ICAM-1). J Exp Med. 1988;167(4):1323–1340.
   PubMed Web of Science ®Google Scholar
• Di Z-H, Ma L, Qi R-Q, et al. T helper 1 and T helper 2 cytokines differentially modulate expression of filaggrin and its processing proteases in human keratinocytes. Chin Med J. 2016;129(3):295–303.
   PubMed Web of Science ®Google Scholar
• Meyer-Hoffert U. Reddish, scaly, and itchy: how proteases and their inhibitors contribute to inflammatory skin diseases. Arch Immunol Ther Exp (Warsz). 2009;57(5):345–354.
   PubMed Web of Science ®Google Scholar
• Netherton EW. A unique case of trichorrhexis nodosa; bamboo hairs—”. AMA Arch Derm. 1958;78(4):483–487.
   PubMedGoogle Scholar
• Smith DL, Smith JG, Wong SW, et al. Netherton’s syndrome: a syndrome of elevated IgE and characteristic skin and hair findings. J Allergy Clin Immunol. 1995;95(1 Pt 1):116–123.
   PubMed Web of Science ®Google Scholar
• Furio L, Hovnanian A. Netherton syndrome: defective kallikrein inhibition in the skin leads to skin inflammation and allergy. Biol Chem. 2014;395(9):945–958.
   PubMed Web of Science ®Google Scholar
• Chavanas S, Bodemer C, Rochat A, et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet. 2000;25(2):141–142.
   PubMed Web of Science ®Google Scholar
• Komatsu N, Takata M, Otsuki N, et al. Elevated stratum corneum hydrolytic activity in Netherton syndrome suggests an inhibitory regulation of desquamation by SPINK5-derived peptides. J Invest Dermatol. 2002;118(3):436–443.
   PubMed Web of Science ®Google Scholar
• Descargues P, Deraison C, Bonnart C, et al. Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity. Nat Genet. 2005;37(1):56–65.
   PubMed Web of Science ®Google Scholar
• Descargues P, Deraison C, Prost C, et al. Corneodesmosomal cadherins are preferential targets of stratum corneum trypsin- and chymotrypsin-like hyperactivity in Netherton syndrome. J Invest Dermatol. 2006;126(7):1622–1632.
   PubMed Web of Science ®Google Scholar
• Furio L, de Veer S, Jaillet M, et al. Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome. J Exp Med. 2014;211(3):499–513.
   PubMed Web of Science ®Google Scholar
• Furio L, Pampalakis G, Michael IP, et al. KLK5 inactivation reverses cutaneous hallmarks of Netherton syndrome. PLoS Genet. 2015;11(9):e1005389.
   PubMed Web of Science ®Google Scholar
• Kasparek P, Ileninova Z, Zbodakova O, et al. KLK5 and KLK7 ablation fully rescues lethality of Netherton syndrome-like phenotype. PLoS Genet. 2017;13(1):e1006566.
   PubMed Web of Science ®Google Scholar
• Wang S, Olt S, Schoefmann N, et al. SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7. Exp Dermatol. 2014;23(7):524–526.
   PubMed Web of Science ®Google Scholar
• Hachem J-P, Wagberg F, Schmuth M, et al. Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome. J Invest Dermatol. 2006;126(7):1609–1621.
   PubMed Web of Science ®Google Scholar
• Komatsu N, Saijoh K, Jayakumar A, et al. Correlation between SPINK5 gene mutations and clinical manifestations in Netherton syndrome patients. J Invest Dermatol. 2008;128(5):1148–1159.
   PubMed Web of Science ®Google Scholar
• Yalcin AD. A case of Netherton syndrome: successful treatment with omalizumab and pulse prednisolone and its effects on cytokines and immunoglobulin levels. Immunopharmacol Immunotoxicol. 2016;38(2):162–166.
   PubMed Web of Science ®Google Scholar
• Roda Â, Mendonça-Sanches M, Travassos AR, et al. Infliximab therapy for Netherton syndrome: a case report. JAAD Case Rep. 2017;3(6):550–552.
   PubMedGoogle Scholar
• Fontao L, Laffitte E, Briot A, et al. Infliximab Infusions for Netherton syndrome: sustained clinical improvement correlates with a reduction of thymic stromal lymphopoietin levels in the skin. J Invest Dermatol. 2011;131(9):1947–1950.
   PubMed Web of Science ®Google Scholar
• Yaghmaie P, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. J Allergy Clin Immunol. 2013;131(2):428–433.
   PubMed Web of Science ®Google Scholar
• Drucker AM, Wang AR, Li W-Q, et al. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26–30.
   PubMed Web of Science ®Google Scholar
• Deckers IAG, McLean S, Linssen S, et al. Investigating international time trends in the incidence and prevalence of atopic eczema 1990–2010: a systematic review of epidemiological studies. PLoS One. 2012;7(7):e39803.
   PubMed Web of Science ®Google Scholar
• Rhodes HL, Sporik R, Thomas P, et al. Early life risk factors for adult asthma: a birth cohort study of subjects at risk. J Allergy Clin Immunol. 2001;108(5):720–725.
   PubMed Web of Science ®Google Scholar
• Rhodes HL, Thomas P, Sporik R, et al. A birth cohort study of subjects at risk of atopy: twenty-two-year follow-up of wheeze and atopic status. Am J Respir Crit Care Med. 2002;165(2):176–180.
   PubMed Web of Science ®Google Scholar
• Schmitt J, Schwarz K, Baurecht H, et al. Atopic dermatitis is associated with an increased risk for rheumatoid arthritis and inflammatory bowel disease, and a decreased risk for type 1 diabetes. J Allergy Clin Immunol. 2016;137(1):130–136.
   PubMed Web of Science ®Google Scholar
• Palmer CNA, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nature Genet. 2006;38(4):441–446.
   PubMed Web of Science ®Google Scholar
• Smith FJ, Irvine AD, Terron-Kwiatkowski A, et al. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet. 2006;38(3):337–342.
   PubMed Web of Science ®Google Scholar
• Weidinger S, O'Sullivan M, Illig T, et al. Filaggrin mutations, atopic eczema, hay fever, and asthma in children. J Allergy Clin Immunol. 2008;121(5):1203–12090.
   PubMed Web of Science ®Google Scholar
• Baurecht H, Irvine AD, Novak N, et al. Toward a major risk factor for atopic eczema: meta-analysis of filaggrin polymorphism data. J Allergy Clin Immunol. 2007;120(6):1406–1412.
   PubMed Web of Science ®Google Scholar
• Hubiche T, Ged C, Benard A, et al. Analysis of SPINK 5, KLK 7 and FLG genotypes in a French atopic dermatitis cohort. Acta Derm Venereol. 2007;87(6):499–505.
   PubMed Web of Science ®Google Scholar
• Vasilopoulos Y, Cork MJ, Murphy R, et al. Genetic association between an AACC insertion in the 3′UTR of the stratum corneum chymotryptic enzyme gene and atopic dermatitis. J Invest Dermatol. 2004;123(1):62–66.
   PubMed Web of Science ®Google Scholar
• Weidinger S, Baurecht H, Wagenpfeil S, et al. Analysis of the individual and aggregate genetic contributions of previously identified serine peptidase inhibitor Kazal type 5 (SPINK5), kallikrein-related peptidase 7 (KLK7), and filaggrin (FLG) polymorphisms to eczema risk. J Allergy Clin Immunol. 2008;122(3):560–80000.
   PubMed Web of Science ®Google Scholar
• Morizane S, Ouchida M, Sunagawa K, et al. Analysis of all 34 exons of the SPINK5 gene in Japanese atopic dermatitis patients. Acta Med Okayama. 2018;72(3):275–282.
   PubMed Web of Science ®Google Scholar
• Fortugno P, Furio L, Teson M, et al. The 420K LEKTI variant alters LEKTI proteolytic activation and results in protease deregulation: implications for atopic dermatitis. Hum Mol Genet. 2012;21(19):4187–4200.
   PubMed Web of Science ®Google Scholar
• Voegeli R, Rawlings AV, Breternitz M, et al. Increased stratum corneum serine protease activity in acute eczematous atopic skin. Br J Dermatol. 2009;161(1):70–77.
   PubMed Web of Science ®Google Scholar
• Voegeli R, Doppler S, Joller P, et al. Increased mass levels of certain serine proteases in the stratum corneum in acute eczematous atopic skin. Int J Cosmet Sci. 2011;33(6):560–565.
   PubMed Web of Science ®Google Scholar
• Komatsu N, Saijoh K, Kuk C, et al. Human tissue kallikrein expression in the stratum corneum and serum of atopic dermatitis patients. Exp Dermatol. 2007;16(6):513–519.
   PubMed Web of Science ®Google Scholar
• Hansson L, Bäckman A, Ny A, et al. Epidermal overexpression of stratum corneum chymotryptic enzyme in mice: a model for chronic itchy dermatitis. J Invest Dermatol. 2002;118(3):444–449.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132.
   PubMed Web of Science ®Google Scholar
• Boguniewicz M, Alexis AF, Beck LA, et al. Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies. J Allergy Clin Immunol Pract. 2017;5(6):1519–1531.
   PubMed Web of Science ®Google Scholar
• de Wijs L, Bosma AL, Erler NS, et al. Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data. Br J Dermatol. 2020;182(2):418–426.
   PubMed Web of Science ®Google Scholar
• Misery L, Huet F, Gouin O, et al. Current pharmaceutical developments in atopic dermatitis. Curr Opin Pharmacol. 2019;46:7–13.
   PubMed Web of Science ®Google Scholar
• Vakharia PP, Silverberg JI. Monoclonal antibodies for atopic dermatitis: progress and potential. BioDrugs. 2017;31(5):409–422.
   PubMed Web of Science ®Google Scholar
• Shi K, Lio PA. Alternative treatments for atopic dermatitis: an update. Am J Clin Dermatol. 2019;20(2):251–266.
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Barker J. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263–271.
   PubMed Web of Science ®Google Scholar
• Schlaak JF, Buslau M, Jochum W, et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol. 1994;102(2):145–149.
   PubMed Web of Science ®Google Scholar
• Komatsu N, Saijoh K, Kuk C, et al. Aberrant human tissue kallikrein levels in the stratum corneum and serum of patients with psoriasis: dependence on phenotype, severity and therapy. Br J Dermatol. 2007;156(5):875–883.
   PubMed Web of Science ®Google Scholar
• Eissa A, Cretu D, Soosaipillai A, et al. Serum kallikrein-8 correlates with skin activity, but not psoriatic arthritis, in patients with psoriatic disease. Clin Chem Lab Med. 2013;51(2):317–325.
   PubMed Web of Science ®Google Scholar
• Iinuma S, Kishibe M, Saito N, et al. Klk8 is required for microabscess formation in a mouse imiquimod model of psoriasis. Exp Dermatol. 2015;24(11):887–901.
   PubMed Web of Science ®Google Scholar
• He Z, Zhan X, Zheng Q, et al. Enhanced expression of kallikrein-related peptidase 7 in lichen planus, lichen sclerosis, porokeratosis and psoriasis vulgaris. J Dermatol Res. 2017;2(2):103–109.
   Google Scholar
• Kishibe M, Bando Y, Terayama R, et al. Kallikrein 8 is involved in skin desquamation in cooperation with other kallikreins. J Biol Chem. 2007;282(8):5834–5841.
   PubMed Web of Science ®Google Scholar
• Kishibe M, Bando Y, Tanaka T, et al. Kallikrein-related peptidase 8-dependent skin wound healing is associated with upregulation of kallikrein-related peptidase 6 and PAR2 . J Invest Dermatol. 2012;132(6):1717–1724.
   PubMed Web of Science ®Google Scholar
• Iinuma S, Kishibe M, Saito N, et al. Kallikrein‐related peptidase 6 promotes psoriasiform skin inflammation through a protease‐activated receptor 2‐independent mechanism. Exp Dermatol. 2017;26(3):289–291.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB. Therapeutic options in the treatment of psoriasis and atopic dermatitis. J Am Acad Dermatol. 2005;53(1):S3–S16.
   PubMed Web of Science ®Google Scholar
• Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866–873.
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Gallo RL. Rosacea as a disease of cathelicidins and skin innate immunity. J Investig Dermatol Symp Proc. 2011;15(1):12–15.
   PubMedGoogle Scholar
• Larrick JW, Hirata M, Balint RF, et al. Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect Immun. 1995;63(4):1291–1297.
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Nardo DA, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007;13(8):975–980.
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Kanada K, Macleod DT, et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Invest Dermatol. 2011;131(3):688–697.
   PubMed Web of Science ®Google Scholar
• Coda AB, Hata T, Miller J, et al. Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel. J Am Acad Dermatol. 2013;69(4):570–577.
   PubMed Web of Science ®Google Scholar
• Two AM, Hata TR, Nakatsuji T, et al. Reduction in serine protease activity correlates with improved rosacea severity in a small, randomized pilot study of a topical serine protease inhibitor. J Invest Dermatol. 2014;134(4):1143–1145.
   PubMed Web of Science ®Google Scholar
• Kanada KN, Nakatsuji T, Gallo RL. Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin. J Invest Dermatol. 2012;132(5):1435–1442.
   PubMed Web of Science ®Google Scholar
• Rezze GG, Fregnani JHH, Duprat J, et al. Cell adhesion and communication proteins are differentially expressed in melanoma progression model. Hum Pathol. 2011;42(3):409–418.
   PubMed Web of Science ®Google Scholar
• Martins WK, Esteves GH, Almeida OMM, et al. Gene network analyses point to the importance of human tissue kallikreins in melanoma progression. BMC Med Genomics. 2011;4:76.
   PubMed Web of Science ®Google Scholar
• Delaunay T, Deschamps L, Haddada M, et al. Aberrant expression of kallikrein-related peptidase 7 is correlated with human melanoma aggressiveness by stimulating cell migration and invasion. Mol Oncol. 2017;11(10):1330–1347.
   PubMed Web of Science ®Google Scholar
• Haddada M, Draoui H, Deschamps L, et al. Kallikrein-related peptidase 7 overexpression in melanoma cells modulates cell adhesion leading to a malignant phenotype. Biol Chem. 2018;399(9):1099–1105.
   PubMed Web of Science ®Google Scholar
• Ghosh MC, Grass L, Soosaipillai A, et al. Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells. Tumour Biol. 2004;25(4):193–199.
   PubMedGoogle Scholar
• Thierauf J, Veit JA, Lennerz JK, et al. Expression of kallikrein-related peptidase 6 in primary mucosal malignant melanoma of the head and neck. Head Neck Pathol. 2017;11(3):314–320.
   PubMed Web of Science ®Google Scholar
• Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80(1):208–250.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Spatz A, Robert C. Cutaneous melanoma. Lancet. 2014;383(9919):816–827.
   PubMed Web of Science ®Google Scholar
• Sotiropoulou G, Pampalakis G. Targeting the kallikrein-related peptidases for drug development. Trends Pharmacol Sci. 2012;33(12):623–634.
   PubMed Web of Science ®Google Scholar
• Prassas I, Eissa A, Poda G, et al. Unleashing the therapeutic potential of human kallikrein-related serine proteases. Nat Rev Drug Discov. 2015;14(3):183–202.
   PubMed Web of Science ®Google Scholar
• Swedberg JE, de Veer SJ, Harris JM. Natural and engineered kallikrein inhibitors: an emerging pharmacopoeia. Biol Chem. 2010;391(4):357–374.
   PubMed Web of Science ®Google Scholar
• Shariff L, Zhu Y, Cowper B, et al. Sunflower trypsin inhibitor (SFTI-1) analogues of synthetic and biological origin via N → S acyl transfer: potential inhibitors of human kallikrein-5 (KLK5). Tetrahedron. 2014;70(42):7675–7680.
   Web of Science ®Google Scholar
• Chen W, Kinsler VA, Macmillan D, et al. Tissue kallikrein inhibitors based on the sunflower trypsin inhibitor scaffold – a potential therapeutic intervention for skin diseases. PloS One. 2016;11(11):e0166268.
   PubMed Web of Science ®Google Scholar
• de Veer SJ, Ukolova SS, Munro CA, et al. Mechanism-based selection of a potent kallikrein-related peptidase 7 inhibitor from a versatile library based on the sunflower trypsin inhibitor SFTI-1. Biopolymers. 2013;100(5):510–518.
   PubMed Web of Science ®Google Scholar
• Murafuji H, Sakai H, Goto M, et al. Structure-based drug design of 1,3,6-trisubstituted 1,4-diazepan-7-ones as selective human kallikrein 7 inhibitors . Bioorg Med Chem Lett. 2018;28(8):1371–1375.
   PubMed Web of Science ®Google Scholar
• Murafuji H, Muto T, Goto M, et al. Discovery and structure–activity relationship of imidazolinylindole derivatives as kallikrein 7 inhibitors. Bioorg Med Chem Lett. 2019;29(2):334–338.
   PubMed Web of Science ®Google Scholar
• Teixeira TSP, Freitas RF, O A, et al. Biological evaluation and docking studies of natural isocoumarins as inhibitors for human kallikrein 5 and 7. Bioorg Med Chem Lett. 2011;21(20):6112–6115.
   PubMed Web of Science ®Google Scholar
• Freitas RF, Teixeira TS, Barros TG, et al. Isomannide derivatives as new class of inhibitors for human kallikrein 7. Bioorg Med Chem Lett. 2012;22(19):6072–6075.
   PubMed Web of Science ®Google Scholar
• Oliveira JP, Freitas RF, Melo LS, et al. Isomannide-based peptidomimetics as inhibitors for human tissue kallikreins 5 and 7. ACS Med Chem Lett. 2014;5(2):128–132.
   PubMed Web of Science ®Google Scholar
• Di Paolo CT, Filippou PS, Yu Y, et al. Screening of chemical libraries in pursuit of kallikrein-5 specific inhibitors for the treatment of inflammatory dermatoses. Clin Chem Lab Med. 2019;57(11):1737–1743.
   PubMed Web of Science ®Google Scholar
• Santos JA, Kondo MYY, Freitas RF, et al. The natural flavone fukugetin as a mixed-type inhibitor for human tissue kallikreins. Bioorg Med Chem Lett. 2016;26(5):1485–1489.
   PubMed Web of Science ®Google Scholar
• Matsubara Y, Matsumoto T, Koseki J, et al. Inhibition of human kallikrein 5 protease by triterpenoids from natural sources. Molecules. 2017;22(11):1829–1812.
   Web of Science ®Google Scholar
• de Souza ASS, Pacheco B, Pinheiro S, et al. 3-Acyltetramic acids as a novel class of inhibitors for human kallikreins 5 and 7. Bioorg Med Chem Lett. 2019;29(9):1094–1098.
   PubMed Web of Science ®Google Scholar
• Limón D, Fábrega MJJ, Calpena AC, et al. Multifunctional serine protease inhibitor-coated water-soluble gold nanoparticles as a novel targeted approach for the treatment of inflammatory skin diseases. Bioconjug Chem. 2018;29(4):1060–1072.
   PubMed Web of Science ®Google Scholar
• Alkuraya FS. Natural human knockouts and the era of genotype to phenotype. Genome Med. 2015;7(1):1–3.
   PubMedGoogle Scholar